499 research outputs found
Beyond the ego network: The effect of distant connections on node anonymity
Ensuring privacy of individuals is of paramount importance to social network
analysis research. Previous work assessed anonymity in a network based on the
non-uniqueness of a node's ego network. In this work, we show that this
approach does not adequately account for the strong de-anonymizing effect of
distant connections. We first propose the use of d-k-anonymity, a novel measure
that takes knowledge up to distance d of a considered node into account.
Second, we introduce anonymity-cascade, which exploits the so-called
infectiousness of uniqueness: mere information about being connected to another
unique node can make a given node uniquely identifiable. These two approaches,
together with relevant "twin node" processing steps in the underlying graph
structure, offer practitioners flexible solutions, tunable in precision and
computation time. This enables the assessment of anonymity in large-scale
networks with up to millions of nodes and edges. Experiments on graph models
and a wide range of real-world networks show drastic decreases in anonymity
when connections at distance 2 are considered. Moreover, extending the
knowledge beyond the ego network with just one extra link often already
decreases overall anonymity by over 50%. These findings have important
implications for privacy-aware sharing of sensitive network data
Simulations of Dust in Interacting Galaxies I: Dust Attenuation
A new Monte-Carlo radiative-transfer code, Sunrise, is used in conjunction
with hydrodynamic simulations of major galaxy mergers to calculate the effects
of dust in such systems. The simulations are in good agreement with
observations of dust absorption in starburst galaxies, and the dust has a
profound effect on their appearance. The dust attenuation increases with
luminosity such that at peak luminosities ~90% of the bolometric luminosity is
absorbed by dust. In general, the detailed appearance of the merging event
depends on the stage of the merger and the geometry of the encounter. The
fraction of bolometric energy absorbed by the dust, however, is a robust
quantity that can be predicted from the intrinsic properties bolometric
luminosity, baryonic mass, star-formation rate, and metallicity of the system.
This paper presents fitting formulae, valid over a wide range of masses and
metallicities, from which the absorbed fraction of luminosity (and consequently
also the infrared dust luminosity) can be predicted. The attenuation of the
luminosity at specific wavelengths can also be predicted, albeit with a larger
scatter due to the variation with viewing angle. These formulae for dust
attenuation appear to be valid for both isolated and interacting galaxies, are
consistent with earlier studies, and would be suitable for inclusion in
theoretical models, e.g. semi-analytic models of galaxy formation.Comment: 12 pages, 10 figures, submitted to Ap
GEMS: Galaxy Evolution from Morphologies and SEDs
GEMS, Galaxy Evolution from Morphologies and SEDs, is a large-area (800
arcmin2) two-color (F606W and F850LP) imaging survey with the Advanced Camera
for Surveys on HST. Centered on the Chandra Deep Field South, it covers an area
of ~28'x28', or about 120 Hubble Deep Field areas, to a depth of
m_AB(F606W)=28.3 (5sigma and m_AB(F850LP)=27.1 (5sigma) for compact sources. In
its central ~1/4, GEMS incorporates ACS imaging from the GOODS project.
Focusing on the redshift range 0.2<=z<=1.1, GEMS provides morphologies and
structural parameters for nearly 10,000 galaxies where redshift estimates,
luminosities and SEDs exist from COMBO-17. At the same time, GEMS contains
detectable host galaxy images for several hundred faint AGN. This paper
provides an overview of the science goals, the experiment design, the data
reduction and the science analysis plan for GEMS.Comment: 24 pages, TeX with 6 eps Figures; to appear in ApJ Supplement. Low
resolution figures only. Full resolution at
http://zwicky.as.arizona.edu/~rix/Misc/GEMS.ps.g
Proarrhythmic proclivity of left-stellate ganglion stimulation in a canine model of drug-induced long-QT syndrome type 1
Background
Left-stellate ganglion stimulation (LSGS) can modify regional dispersion of ventricular refractoriness, promote triggered activity, and reduce the threshold for ventricular fibrillation (VF). Sympathetic hyperactivity precipitates torsades de pointes (TdP) and VF in susceptible patients with long-QT syndrome type 1 (LQT1). We investigated the electromechanical effects of LSGS in a canine model of drug-induced LQT1, gaining novel arrhythmogenic insights.
Methods
In nine mongrel dogs, the left and right stellate ganglia were exposed for electrical stimulation. ECG, left- and right-ventricular endocardial monophasic action potentials (MAPs) and pressures (LVP, RVP) were recorded. The electromechanical window (EMW; Q to LVP at 90% relaxation minus QT interval) was calculated. LQT1 was mimicked by infusion of the KCNQ1/IKs blocker HMR1556.
Results
At baseline, LSGS and right-stellate ganglion stimulation (RSGS) caused similar heart-rate acceleration and QT shortening. Positive inotropic and lusitropic effects were more pronounced under LSGS than RSGS. IKs blockade prolonged QTc, triggered MAP-early afterdepolarizations (EADs) and rendered the EMW negative, but no ventricular tachyarrhythmias occurred. Superimposed LSGS exaggerated EMW negativity and evoked TdP in 5/9 dogs within 30 s. Preceding extrasystoles originated mostly from the outflow-tracts region. TdP deteriorated into therapy-refractory VF in 4/5 animals. RSGS did not provoke TdP/VF.
Conclusions
In this model of drug-induced LQT1, LSGS readily induced TdP and VF during repolarization prolongation and MAP-EAD generation, but only if EMW turned from positive to very negative. We postulate that altered mechano-electric coupling can exaggerate regional dispersion of refractoriness and facilitates ventricular ectopy
Limited added value of laboratory monitoring in thiopurine maintenance monotherapy in inflammatory bowel disease patients
Background: To timely detect myelotoxicity and hepatotoxicity, laboratory monitoring at 3-month intervals is advised throughout thiopurine maintenance treatment for IBD. However, reported incidence rates of myelotoxicity and hepatotoxicity in maintenance treatment are low. Aim: To assess incidence rates and clinical consequences of myelotoxicity and hepatotoxicity in thiopurine maintenance therapy after at least 1 year of thiopurine treatment. Methods: Retrospective analysis of therapy adjustment for laboratory toxicity in adult IBD patients after 12 consecutive months of azathioprine (AZA) or mercaptopurine monotherapy (ie baseline) between 2000 and 2016. Incidence rates of laboratory toxicity (ie myelotoxicity [leucocyte count <4.0 × 10e9/L, and/or platelet count <150 × 10e9/L] and/or hepatotoxicity (gamma-glutamyltransferase [GGT], alkaline phosphatase [AP], ALT and/or AST above ULN, excluding isolated increased AST/AP]) and associated diagnostic procedures and complications were assessed. Results: In total, 12.391 laboratory assessments were performed on 1132 patients (56% female, AZA 74%) during 3.3 years of median follow-up. Median monitoring frequency was 3.1 assessments/treatment year. Only 83/12.391 (0.7%) assessments resulted in therapy adjustment, dose reduction in 46 patients, cessation in 28 and allopurinol initiation in nine; risk of therapy adjustment was 1.9% per treatment year. Incidence rates of myelotoxicity were 7.1% (5.1% mild/1.8% moderate/0.1% severe) and hepatotoxicity 5.1% (3.8% mild/1.1% moderate/0.2% severe) per treatment year. Treatment-related complications with concurrent laboratory toxicity occurred in 12 patients (1.1%) and would not have been prevented by monitoring. Conclusion: Severe laboratory toxicity is uncommon after 1 year of thiopurine monotherapy at 4-month monitoring intervals. Therapy adjustments are rare after detection of laboratory toxicity. After 1 year of thiopurine monotherapy, laboratory monitoring may be lowered to less than a 4-month interval
Vedolizumab for Inflammatory Bowel Disease:Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab
Contains fulltext :
220028.pdf (Publisher’s version ) (Open Access)Prospective data of vedolizumab treatment for patients with inflammatory bowel disease (IBD) beyond 1 year of treatment is scarce but needed for clinical decision making. We prospectively enrolled 310 patients with IBD (191 with Crohn's disease (CD) and 119 patients with ulcerative colitis (UC)) with a follow-up period of 104 weeks (interquartile range: 103-104) in a nationwide registry. The corticosteroid-free clinical remission rate (Harvey Bradshaw Index ≤ 4, Short Clinical Colitis Activity index ≤ 2) at weeks 52 and 104 were 28% and 19% for CD and 27% and 28% for UC, respectively. Fifty-nine percent maintained corticosteroid-free clinical remission between weeks 52 and 104. Vedolizumab with concomitant immunosuppression showed comparable effectiveness outcomes compared with vedolizumab monotherapy (week 104: 21% vs. 23%; P = 0.77), whereas 8 of 13 severe infections occurred in patients treated with concomitant immunosuppression. To conclude, the clinical effect was 19% for CD and 28% for UC after 2 years of follow-up regardless of concomitant immunosuppression
Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry – Vedolizumab
Prospective data of vedolizumab treatment for patients with inflammatory bowel disease (IBD) beyond 1 year of treatment is scarce but needed for clinical decision making. We prospectively enrolled 310 patients with IBD (191 with Crohn's disease (CD) and 119 patients with ulcerative colitis (UC)) with a follow-up period of 104 weeks (interquartile range: 103–104) in a nationwide registry. The corticosteroid-free clinical remission rate (Harvey Bradshaw Index ≤ 4, Short Clinical Colitis Activity index ≤ 2) at weeks 52 and 104 were 28% and 19% for CD and 27% and 28% for UC, respectively. Fifty-nine percent maintained corticosteroid-free clinical remission between weeks 52 and 104. Vedolizumab with concomitant immunosuppression showed comparable effectiveness outcomes compared with vedolizumab monotherapy (week 104: 21% vs. 23%; P = 0.77), whereas 8 of 13 severe infections occurred in patients treated with concomitant immunosuppression. To conclude, the clinical effect was 19% for CD and 28% for UC after 2 years of follow-up regardless of concomitant immunosuppression
Engaging stakeholders to level up COPD care in LMICs:lessons learned from the "Breathe Well" programme in Brazil, China, Georgia, and North Macedonia
BACKGROUND: Effective stakeholder engagement in health research is increasingly being recognised and promoted as an important pathway to closing the gap between knowledge production and its use in health systems. However, little is known about its process and impacts, particularly in low-and middle-income countries. This opinion piece draws on the stakeholder engagement experiences from a global health research programme on Chronic Obstructive Pulmonary Disease (COPD) led by clinician researchers in Brazil, China, Georgia and North Macedonia, and presents the process, outcomes and lessons learned.MAIN BODY: Each country team was supported with an overarching engagement protocol and mentored to develop a tailored plan. Patient involvement in research was previously limited in all countries, requiring intensive efforts through personal communication, meetings, advisory groups and social media. Accredited training programmes were effective incentives for participation from healthcare providers; and aligning research findings with competing policy priorities enabled interest and dialogue with decision-makers. The COVID-19 pandemic severely limited possibilities for planned engagement, although remote methods were used where possible. Planned and persistent engagement contributed to shared knowledge and commitment to change, including raised patient and public awareness about COPD, improved skills and practice of healthcare providers, increased interest and support from clinical leaders, and dialogue for integrating COPD services into national policy and practice.CONCLUSION: Stakeholder engagement enabled relevant local actors to produce and utilise knowledge for small wins such as improving day-to-day practice and for long-term goals of equitable access to COPD care. For it to be successful and sustained, stakeholder engagement needs to be valued and integrated throughout the research and knowledge generation process, complete with dedicated resources, contextualised and flexible planning, and commitment.</p
The Lick AGN Monitoring Project: Broad-Line Region Radii and Black Hole Masses from Reverberation Mapping of Hbeta
We have recently completed a 64-night spectroscopic monitoring campaign at
the Lick Observatory 3-m Shane telescope with the aim of measuring the masses
of the black holes in 12 nearby (z < 0.05) Seyfert 1 galaxies with expected
masses in the range ~10^6-10^7 M_sun and also the well-studied nearby active
galactic nucleus (AGN) NGC 5548. Nine of the objects in the sample (including
NGC 5548) showed optical variability of sufficient strength during the
monitoring campaign to allow for a time lag to be measured between the
continuum fluctuations and the response to these fluctuations in the broad
Hbeta emission. We present here the light curves for the objects in this sample
and the subsequent Hbeta time lags for the nine objects where these
measurements were possible. The Hbeta lag time is directly related to the size
of the broad-line region, and by combining the lag time with the measured width
of the Hbeta emission line in the variable part of the spectrum, we determine
the virial mass of the central supermassive black hole in these nine AGNs. The
absolute calibration of the black hole masses is based on the normalization
derived by Onken et al. We also examine the time lag response as a function of
velocity across the Hbeta line profile for six of the AGNs. The analysis of
four leads to ambiguous results with relatively flat time lags as a function of
velocity. However, SBS 1116+583A exhibits a symmetric time lag response around
the line center reminiscent of simple models for circularly orbiting broad-line
region (BLR) clouds, and Arp 151 shows an asymmetric profile that is most
easily explained by a simple gravitational infall model. Further investigation
will be necessary to fully understand the constraints placed on physical models
of the BLR by the velocity-resolved response in these objects.Comment: 24 pages, 16 figures and 13 tables, submitted to Ap
Tofacitinib for ulcerative colitis:results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
Background: Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC). Aim: To evaluate effectiveness, safety and use of tofacitinib in daily practice. Methods: UC patients initiating tofacitinib were prospectively enrolled in 15 hospitals in the Netherlands. Corticosteroid-free clinical remission (short clinical colitis activity index [SCCAI] ≤2), biochemical remission (faecal calprotectin level ≤250 µg/g), combined corticosteroid-free clinical and biochemical remission, predictors of remission, safety outcomes, treatment dose and effect on lipids were determined at weeks 12 and 24. Endoscopic outcomes were evaluated in centres with routine endoscopic evaluation. Results: In total, 123 UC patients (95% anti-TNF, 62% vedolizumab and 3% ustekinumab experienced) were followed for a median duration of 24 weeks (interquartile range 12-26). The proportion of patients in corticosteroid-free clinical, biochemical, and combined corticosteroid-free clinical and biochemical remission rate at week 24 was 29% (n: 22/77), 25% (n: 14/57), and 19% (n: 11/57) respectively. Endoscopic remission (Mayo = 0) was achieved in 21% of patients at week 12 (n: 7/33). Prior vedolizumab exposure was associated with reduced clinical remission (odds ratio 0.33, 95% confidence interval [CI] 0.11-0.94). At week 24, 33% (n: 14/42) of patients still on tofacitinib treatment used 10 mg twice daily. In total, 33 tofacitinib-related adverse events (89 per 100 patient years) occurred, 7 (6% of total cohort) resulted in discontinuation. Cholesterol, HDL and LDL levels increased during induction treatment by 18% (95% CI 9-26), 18% (95% CI 8-28) and 21% (95% CI 14-39) respectively. Conclusion: Tofacitinib is an effective treatment for UC after anti-TNF and vedolizumab failure. However, a relatively high rate of adverse events was observed resulting in discontinuation in 6% of patients
- …